{"entity":{"id":"monika-hegi","kind":"person","name":"Monika E. Hegi","aka":[],"tldr":"Showed that MGMT promoter methylation predicts benefit from temozolomide, the biomarker every glioblastoma patient is now tested for.","summary":"Monika Hegi led the 2005 NEJM study, companion to the Stupp trial, showing that glioblastoma patients with a methylated MGMT promoter gain most from temozolomide chemoradiotherapy, establishing the first predictive biomarker in neuro-oncology and the basis for treatment selection in elderly patients. She leads translational research for EORTC brain tumour trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hegi%20ME%5BAuthor%5D%20MGMT"}],"tags":["glioma","biomarkers","mgmt"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["methylation-profiling"],"targets":[],"drugs":[],"companies":[],"institutions":["chuv-lausanne"],"pathways":[],"terms":[],"trials":["eortc-26981"],"people":[],"bottlenecks":[],"keyPapers":["paper-stupp-temozolomide-nejm-2005"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Head of the Laboratory of Brain Tumor Biology and Genetics, Lausanne University Hospital (CHUV)","institutionId":"chuv-lausanne","specialisms":["Glioblastoma","MGMT methylation","Tumour biomarkers","Translational neuro-oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hegi%20ME%5BAuthor%5D%20MGMT"}],"papers":[{"title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","journal":"NEJM","year":2005,"doi":"10.1056/NEJMoa043331"},{"title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","journal":"Lancet Oncology","year":2009,"doi":"10.1016/S1470-2045(09)70025-7"},{"title":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","journal":"New England Journal of Medicine","year":2005,"url":"https://doi.org/10.1056/NEJMoa043330","doi":"10.1056/NEJMoa043330"}],"orcid":"0000-0003-0855-6495"},"route":"/people/monika-hegi/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"technology":[{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/"}],"institution":[{"id":"chuv-lausanne","kind":"institution","name":"Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne","route":"/institutions/chuv-lausanne/"}],"trial":[{"id":"eortc-26981","kind":"trial","name":"EORTC 26981 / NCIC CE.3 (Stupp trial)","route":"/trials/eortc-26981/"}],"paper":[{"id":"paper-stupp-temozolomide-nejm-2005","kind":"paper","name":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","route":"/key-papers/paper-stupp-temozolomide-nejm-2005/"}]}}